Trastuzumab-induced cardiac dysfunction: A ‘dual-hit’

Trastuzumab (Trz) is a monoclonal antibody against the human epidermal growth factor receptor 2 that is found to be overexpressed in 25% to 30% of breast cancer patients. In spite of the therapeutic benefits of Trz, cardiotoxic side effects are still an issue. This effect is potentiated particularly...

Full description

Saved in:
Bibliographic Details
Main Authors: Zeglinski, Matthew, Ludke, Ana, Jassal, Davinder S, Singal, Pawan K
Format: Artigo
Language:Inglês
Published: Pulsus Group Inc 2011
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3209542/
https://ncbi.nlm.nih.gov/pubmed/22065936
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items